Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.6590
-0.0109 (-1.63%)
May 20, 2025, 4:00 PM - Market closed
Biofrontera Employees
As of December 31, 2024, Biofrontera had 93 total employees, including 92 full-time and 1 part-time employees. The number of employees increased by 8 or 9.41% compared to the previous year.
Employees
93
Change (1Y)
8
Growth (1Y)
9.41%
Revenue / Employee
$408,570
Profits / Employee
-$123,925
Market Cap
5.85M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 93 | 8 | 9.41% |
| Dec 31, 2023 | 85 | 4 | 4.94% |
| Dec 31, 2022 | 81 | 12 | 17.39% |
| Dec 31, 2021 | 69 | 13 | 23.21% |
| Dec 31, 2020 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BFRI News
- 4 days ago - Biofrontera Inc. (BFRI) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 5 days ago - Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris - GlobeNewsWire
- 14 days ago - Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025 - Accesswire
- 19 days ago - Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis - GlobeNewsWire
- 2 months ago - Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk - GlobeNewsWire